Revenue
2020
2021
2022
2023
2024
2025
RAPID MICRO BIOSYSTEMS, INC. (RPID)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M | $16.1M |
| Research & development | $13.6M | $14.6M | $12.8M | $12.9M | $9.8M | $6.5M |
| Operating income | −$47.4M | −$49.9M | −$56.6M | −$63.2M | −$47.2M | −$30.5M |
| EBITDAderived | −$44.1M | −$46.6M | −$53.5M | −$60.4M | −$45.7M | −$29.0M |
| Net income | −$47.1M | −$46.9M | −$52.5M | −$60.8M | −$73.5M | −$37.1M |
| Basic EPSper diluted share | -$1.05 | -$1.08 | -$1.22 | -$1.43 | -$3.94 | -$126.11 |
| Diluted EPSper diluted share | -$1.05 | -$1.08 | -$1.22 | -$1.43 | -$3.94 | -$126.11 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 | Bain Capital Life Sciences Fund, L.P. +3TenPercentOwner | BuySeries B Warrant (right to buy) · derivative · indirect | 1.46M | — | — | 1.46M |
| May 20, 2026Form 4 | Bain Capital Life Sciences Fund, L.P. +3TenPercentOwner | BuySeries A Warrant (right to buy) · derivative · indirect | 1.46M | — | — | 1.46M |
| May 20, 2026Form 4 | Bain Capital Life Sciences Fund, L.P. +3TenPercentOwner | BuyPre-Funded Warrant (right to buy) · derivative · indirect | 1.46M | — | — | 1.46M |
| Mar 11, 2026Form 4 | Wilson John J. AddingtonCHIEF OPERATING OFFICER | SellClass A Common Stock | 9.6K | $4.32 | $41.5K | 316.8K |
| Mar 11, 2026Form 4 | WIRTJES SEAN MCHIEF FINANCIAL OFFICER | SellClass A Common Stock | 7.5K | $4.32 | $32.3K | 556.2K |